Cancer Control & Prevention Committees

Leadership
Vice-Chair NCORP: ............. Dawn L. Hershman, MD, MS
Cancer Care Delivery Co-Chairs: .................. Dawn L. Hershman, MD, MS
........................................................................... Scott D. Ramsey, MD, PhD
Cancer Survivorship Co-Chairs: .................. Halle C.F. Moore, MD
........................................................................... Melinda L. Irwin, PhD, MPH
Palliative & End of Life Co-Chairs: .................. Robert S. Krouse, MD, FACS
........................................................................... Marie Bakitas, DNSc, CRNP
Prevention and Epidemiology Co-Chairs: ............ Banu Arun, MD
........................................................................... Marian L. Neuhouser, PhD, RD
Symptom Control & QOL Co-Chairs: .................. Michael J. Fisch, MD, MPH
........................................................................... Norah Lynn Henry, MD, PhD
Executive Officers: .................. Katherine D. Crew, MD (CCD, Prevention, Survivorship)
........................................................................... Virginia Sun, PhD, MSN, RN (Palliative, Survivorship)
Senior Advisor: .................. Frank L. Meyskens, Jr., MD
Statisticians: .................. Katherine Guthrie, PhD
........................................................................... Amy Jo Koffarnus, BS, CCRP
........................................................................... Joseph M. Unger, PhD
........................................................................... Kathryn B. Arnold, MS
........................................................................... Amy K. Darke, MS
........................................................................... Danika Lew, MA
........................................................................... Sarah Colby, MS
Administrative Lead SDMC: .................. Monica Yee, CCRP

Scientific Leadership
NCORP Representative: .................. Scott Edward Delacroix, Jr., MD
.................................................... Helen Heng-Shan Moon, MD
Radiation Oncology: .................. Eileen P. Connolly, MD, PhD (CCD, Prevention)
.................................................... Kiri A. Cook, MD (Survivorship, Symptom Control)
.................................................... Erin F. Gillespie, MD (Symptom Control)
Surgery Committee: .................. Robert S. Krouse, MD, FACS
Translational Medicine: .................. James Rae, PhD
Liaisons:
Barlogie-Salmon Myeloma Committee: ............. Charles S. Kuzma, MD
Breast Committee: .................. Mariya Rozenblit, MD (Survivorship)
.................................................... Helen K. Chew, MD (Symptom Control)
.................................................... Dawn Hershman, MD, MS (CCD)
.................................................... Banu Arun, MD (Prevention)
.................................................... Philip Lammers, MD
Early Therapeutics & Rare Cancers: .................. Lara E. Davis, MD (Survivorship)
.................................................... Jason M. Prosek, MD
Gastrointestinal Committee: .................. Jason A. Zell, DO (Prevention)
.................................................... Afshaneh Barzi, MD (CCD)
Genitourinary Committee: .................. Clara Hwang, MD
.................................................... Sarah P. Psutka, MD
International Liaison: .................. Kathy S. Albain, MD
Leukemia Committee: .................. Stephanie B. Tsai, MD
Lung Committee: .................. Gary E. Goodman, MD
Lymphoma Committee: .................. Hayder Saeed, MD
Melanoma Committee: .................. Sancy Leachman, MD, PhD
.................................................... Thach-Giao Truong, MD (Survivorship)
Recruitment & Retention: .................. Allison M. Caban-Holt, PhD
Digital Engagement: .................. Jennifer R. Klemp, PhD (Survivorship)
.................................................... Krishna Soujanya Gunuru, MD (Survivorship)
.................................................... Mina S. Sedrak, MD (CCD)
.................................................... Katherine D. Crew, MD (Prevention)
.................................................... Michael J. Fisch, MD (Symptom Control)
Veterans Affairs: .................. Yeun-Hee Anna Park, MD (Symptom Control)
.................................................... Neha Patel, MD (Survivorship)
.................................................... Jacqueline Ann Gesek, BSN, RN (Nursing)

Designates
Oncology Research Professionals:
CRAs: .................. Amanda R. Dinsdale, MHA, CCRC
.................................................... Amy Jo Koffarnus, BS, CCRP
.................................................... Samantha Wright, MS, CCRP
.................................................... Shirley S. Sui, BS
Nurses: .................. Connie Szczepanek, RN, BSN
.................................................... Melissa F. W. Fou, MSN, RN
Pharmaceutical Sciences Committee: .................. Kimberly McConnell, PharmD
.................................................... Siu-Fun Wong, PharmD
.................................................... Sun “Coco” Yang, PharmD, PhD
SDMC Data Coordinators: .................. Kimberly Carvalho, BA
.................................................... Sam Dzingle, BA
.................................................... Matthew Eng, PharmD
.................................................... Diane Liggett, BS, CCRP
.................................................... Roxanne Topacio, CCRP
.................................................... Monica Yee, BA, CCRP
Recruitment & Retention Specialist: .................. Jamie Sundstrom, BS
Patient Advocates: .................. Barbara Segarra-Vazquez, DHSc (CCD)
.................................................... Amy Geschwender, PhD (Symptom Control)
.................................................... Hartley “Lee” M. Jones, MBA (Survivorship)
.................................................... Cheryl L. Jernigan, CPA (Prevention)
.................................................... Valerie Fraser (Palliative)
Sr. Protocol Project Manager (CCD and Prevention): .................. Patricia O’Kane
Protocol Project Manager (Survivorship): .................. Megan Keim
Protocol Project Manager (Symptom Control): .................. Justine Trevino
Protocol Project Manager (Palliative Care): .................. Andrea Garcia
Clinical Trials Program Manager (Palliative Care): .................. Laura Gildner, MS
Clinical Trials Program Manager (CCD; Prevention; Survivorship; Symptom Control): .................. Mariah Norman, MS
Symptom Control & Quality of Life Committee

Leadership
Co-Chairs: ................................................... Michael J. Fisch, MD, MPH
................................................................. Norah Lynn Henry, MD, PhD

Time/Location
Thursday, April 4, 2024  10:15 a.m. - 12:15 p.m.
Room: Elwha AB (Level 5)

Agenda

Presentations
Integrative Oncology: Emerging Paradigms of Care Delivery and Priority Research Questions; Plenary speaker: Richard T. Lee, MD

Immunotherapy response and toxicity: the role of lifestyle factors; Plenary Speaker: Jennifer L. McQuade MD, MS, MA, LAc

Active Studies


Other Concepts in Development
Weight management prior to radical prostatectomy to improve quality of life and obesity-driven prostate cancer biomarkers. Dr. Hamilton-Reeves

A phase III study evaluating a mindfulness tool to ameliorate treatment-related fatigue in patients with advanced renal cell carcinoma (RCC) Drs. Bergerot and Pal

Emerging from the Haze™ (Haze)- A multi-dimensional, psycho-educational, cognitive rehabilitation program to improve perceived cognitive function for cancer survivors. Dr. Myers

Acupuncture to decrease symptom burden in patients with metastatic breast cancer. Dr. Greenlee

Closed Studies


Committee Business
1. What other studies are we planning?
2. What is happening with our open studies?
3. What other updates should we know about?
   • Patient Advocate Update
   • Statistical Center Update

Other SWOG Studies with Symptom Control and QOL Component
Breast

Cancer Care Delivery
S1703, “Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease
Symptom Control & Quality of Life Committee


GU

S1802, “Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer.” Dr. Chapin. Activated: 9/17/18.


Leukemia


Lung


Lymphoma


S1918, “A Phase II/III Randomized Study of R-miniCHOP with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.” Drs. Brem, Smith, Henry, et al. Activated: 3/19/21.

Myeloma


Prevention and Epidemiology


NCTN Studies

Symptom Control & Quality of Life Committee

Publications

The publications listed below were received by the Group Chair’s Office as published (including online), accepted, or submitted since the SWOG Fall 2023 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are ommitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts


Submitted Manuscripts

## Symptom Control & Quality of Life Committee

**Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study**

<table>
<thead>
<tr>
<th>Institution</th>
<th>S1600</th>
<th>S1614</th>
<th>S2010</th>
<th>S2013</th>
<th>S2205</th>
<th>A221005</th>
<th>A222004</th>
<th>EAQ202</th>
<th>NRGCC010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ascension Providence Hospitals - Southfield</td>
<td>-</td>
<td>-</td>
<td>29</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Audie L Murphy VA Hospital</td>
<td>-</td>
<td>-</td>
<td>11</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Banner MD Anderson Cancer Center</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Banner University Medical Center - Tucson</td>
<td>-</td>
<td>-</td>
<td>4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Bay Area Tumor Institute NCORP</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center</td>
<td>5</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CWRU Case Comprehensive Cancer Center LAPS</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cancer Research for the Ozarks NCORP</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cancer Research of Wisconsin and Northern Michigan Consortium</td>
<td>-</td>
<td>-</td>
<td>97</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Carle Cancer Center NCI Community Oncology Research Program</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>14</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>City of Hope Comprehensive Cancer Center</td>
<td>6</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Columbia University Minority Underserved NCORP</td>
<td>-</td>
<td>-</td>
<td>24</td>
<td>8</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Columbus NCI Community Oncology Research Program</td>
<td>-</td>
<td>-</td>
<td>29</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CommonSpirit Health Research Institute</td>
<td>-</td>
<td>-</td>
<td>7</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Dayton NCI Community Oncology Research Program</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fred Hutchinson Cancer Research Center LAPS</td>
<td>13</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Georgia Cares Minority Underserved NCORP</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>14</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Georgia NCI Community Oncology Research Program</td>
<td>-</td>
<td>-</td>
<td>4</td>
<td>64</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Grupo Oncologico Cooperativo de Investigacion</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Gulf South Minority Underserved NCORP</td>
<td>1</td>
<td>-</td>
<td>2</td>
<td>22</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>5</td>
</tr>
<tr>
<td>Hawaii Minority Underserved NCORP</td>
<td>-</td>
<td>-</td>
<td>3</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Heartland Cancer Research NCORP</td>
<td>-</td>
<td>-</td>
<td>15</td>
<td>210</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Henry Ford Hospital</td>
<td>8</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Instituto Nacional de Enfermedades Neoplasicas</td>
<td>-</td>
<td>-</td>
<td>13</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Kaiser Permanente NCI Community Oncology Research Program</td>
<td>-</td>
<td>2</td>
<td>9</td>
<td>57</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lahey Hospital and Medical Center</td>
<td>-</td>
<td>-</td>
<td>5</td>
<td>52</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Massachusetts Veterans Epidemiology Research and Information Center</td>
<td>-</td>
<td>-</td>
<td>47</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Mercy Medical Center - Des Moines</td>
<td>-</td>
<td>-</td>
<td>9</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Michigan Cancer Research Consortium NCORP</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
# Symptom Control & Quality of Life Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

<table>
<thead>
<tr>
<th>Institution</th>
<th>S1600</th>
<th>S1614</th>
<th>S2010</th>
<th>S2013</th>
<th>S2205</th>
<th>A221805</th>
<th>A222004</th>
<th>EAQ202</th>
<th>NRGCC010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Montana Cancer Consortium NCORP</td>
<td>-</td>
<td>-</td>
<td>4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>NCORP of the Carolinas (Prisma Health NCORP)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>39</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Nevada Cancer Research Foundation NCORP</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>New Mexico Minority Underserved NCORP</td>
<td>-</td>
<td>-</td>
<td>7</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Northwestern University LAPS</td>
<td>-</td>
<td>-</td>
<td>4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Oregon Health and Science University</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>12</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pacific Cancer Research Consortium NCORP</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SCL Health Saint Joseph Hospital</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>STCC at DHR Health Institute for Research and Development</td>
<td>-</td>
<td>-</td>
<td>8</td>
<td>40</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Southeast Clinical Oncology Research Consortium NCORP</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>120</td>
<td>14</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>The Don and Sybil Harrington Cancer Center</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>UC Davis Comprehensive Cancer Center LAPS</td>
<td>-</td>
<td>-</td>
<td>5</td>
<td>9</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>UC Irvine Health/Chao Family Comprehensive Cancer Center</td>
<td>-</td>
<td>-</td>
<td>6</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>USC Norris Comprehensive Cancer Center LAPS</td>
<td>78</td>
<td>-</td>
<td>-</td>
<td>10</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Universidad de la Republica - Facultad de Medicina</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>13</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>University of Arkansas for Medical Sciences</td>
<td>-</td>
<td>-</td>
<td>4</td>
<td>21</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>University of Colorado Cancer Center LAPS</td>
<td>14</td>
<td>-</td>
<td>-</td>
<td>30</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>University of Kansas Cancer Center - MCA Rural MU NCORP</td>
<td>51</td>
<td>-</td>
<td>6</td>
<td>69</td>
<td>8</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>University of Michigan Comprehensive Cancer Center LAPS</td>
<td>-</td>
<td>-</td>
<td>13</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>University of Mississippi Medical Center</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>University of Rochester LAPS</td>
<td>16</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>University of Texas Health Science Center at San Antonio</td>
<td>-</td>
<td>-</td>
<td>7</td>
<td>45</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>University of Texas MD Anderson Cancer Center LAPS</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>University of Utah - Huntsman Cancer Institute LAPS</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Wisconsin NCI Community Oncology Research Program</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>24</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ALLIANCE</td>
<td>5</td>
<td>-</td>
<td>9</td>
<td>280</td>
<td>15</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ECOG-ACRIN</td>
<td>4</td>
<td>-</td>
<td>8</td>
<td>90</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>NRG</td>
<td>2</td>
<td>1</td>
<td>19</td>
<td>194</td>
<td>7</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>203</td>
<td>4</td>
<td>162</td>
<td>1,662</td>
<td>58</td>
<td>8</td>
<td>3</td>
<td>43</td>
<td>5</td>
</tr>
</tbody>
</table>